Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrathecal pemetrexed for refractory leptomeningeal metastasis in NSCLC
ChiCTR2200057235Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in non-small cell lung cancer (NSCLC) and Carcinomatous Meningitis (CM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Overall survival. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
pemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)Carcinomatous Meningitis (CM)
Beyond the preview
Go deeper on ChiCTR2200057235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057235.